APG Asset Management N.V. acquired a new position in shares of Elanco Animal Health (NYSE:ELAN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 36,400 shares of the company’s stock, valued at approximately $1,080,000.
Other hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC purchased a new stake in Elanco Animal Health in the 4th quarter valued at about $18,592,000. Deutsche Bank AG purchased a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $60,000. Comerica Bank purchased a new stake in shares of Elanco Animal Health during the 1st quarter worth approximately $384,000. First Allied Advisory Services Inc. purchased a new stake in shares of Elanco Animal Health during the 1st quarter worth approximately $228,000. Finally, First Mercantile Trust Co. purchased a new stake in shares of Elanco Animal Health during the 1st quarter worth approximately $65,000.
In related news, major shareholder Dawei Li acquired 1,384,717 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average cost of $1.05 per share, with a total value of $1,453,952.85. Also, Director Deborah Turner Kochevar acquired 1,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were bought at an average cost of $27.95 per share, with a total value of $27,950.00. In the last quarter, insiders bought 1,497,497 shares of company stock worth $4,457,115. Insiders own 0.04% of the company’s stock.
Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.26 by $0.02. The business had revenue of $781.60 million for the quarter, compared to analyst estimates of $781.49 million. Elanco Animal Health had a net margin of 4.69% and a return on equity of 7.83%. The company’s revenue was up 1.5% compared to the same quarter last year. On average, analysts expect that Elanco Animal Health will post 1.08 EPS for the current year.
Several research firms recently commented on ELAN. Cleveland Research reaffirmed a “hold” rating on shares of Elanco Animal Health in a report on Thursday, September 26th. Goldman Sachs Group began coverage on shares of Elanco Animal Health in a report on Monday, September 9th. They issued a “positive” rating for the company. They noted that the move was a valuation call. Barclays began coverage on shares of Elanco Animal Health in a report on Monday, September 23rd. They issued an “overweight” rating and a $36.00 price objective for the company. Zacks Investment Research downgraded shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a report on Friday, September 6th. Finally, UBS Group raised shares of Elanco Animal Health from a “sell” rating to a “neutral” rating and cut their price target for the company from $31.00 to $30.00 in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Elanco Animal Health has an average rating of “Hold” and an average target price of $33.98.
Elanco Animal Health Profile
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
See Also: Analyst Ratings Trading
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.